Position in PFE
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$53,751,269
+$1,667,466 QoQ
Shares Held
1,914,219
-8.5% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 67.98605593194928.ToString("F0")%
Shared 0.ToString("F0")%
None 32.01394406805073.ToString("F0")%
Common Shares in PFE Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026CAUSEWAY CAPITAL MANAGEMENT LLC holds $1,766,978,720 across 8 Drug Manufacturers - General names. PFE ranks #3 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
7,421,749 | $1,463,717,337 | |
| 2 | MRK |
Merck & Co., Inc.
|
854,212 | $102,753,161 | |
| 3 | PFE |
Pfizer Inc
This page
|
1,914,219 | $53,751,269 | |
| 4 | BIIB |
Biogen Inc.
|
280,783 | $51,475,947 | |
| 5 | SNY |
Sanofi
|
1,064,516 | $51,288,380 | |
| 6 | NVO |
Novo Nordisk A S
|
1,174,213 | $43,152,327 | |
| 7 | GSK |
GSK plc
|
11,110 | $613,160 | |
| 8 | NVS |
Novartis AG
|
1,487 | $227,139 |
All Filings in PFE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $53,751,269 | 1,914,219 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $52,083,803 | 2,091,719 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $52,795,757 | 2,072,047 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $47,590,682 | 1,963,312 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $51,294,621 | 2,024,255 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $48,623,918 | 1,832,790 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $63,995,311 | 2,211,310 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $56,062,378 | 2,003,659 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||